What is the current Bio-Techne market capitalization?
The current market capitalization of Bio-Techne is 10.6 B USD.
Bio-Techne Market capitalization 2025
Bio-Techne Market capitalization
10.6 B USD
Ticker
TECH
ISIN
US09073M1045
WKN
A12ENG
In 2025, Bio-Techne's market cap stood at 10.6 B USD, a -12.6% increase from the 12.13 B USD market cap in the previous year.
The Bio-Techne Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2024 | 11.81 |
| 2023 | 12.23 |
| 2022 | 14.87 |
| 2021 | 17.88 |
| 2020 | 9.76 |
| 2019 | 7.71 |
| 2018 | 6.08 |
| 2017 | 4.3 |
| 2016 | 3.79 |
| 2015 | 3.6 |
| 2014 | 3.36 |
| 2013 | 2.75 |
| 2012 | 2.58 |
| 2011 | 2.69 |
| 2010 | 2.32 |
| 2009 | 2.3 |
| 2008 | 2.78 |
| 2007 | 2.39 |
| 2006 | 2.16 |
| 2005 | 1.93 |
Bio-Techne Aktienanalyse
What does Bio-Techne do?
Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Bio-Techne's Market Capitalization
Bio-Techne's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Bio-Techne's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Bio-Techne's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Bio-Techne’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Bio-Techne stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Bio-Techne.
How has the market capitalization of Bio-Techne developed in recent years?
The market capitalization of Bio-Techne has increased/decreased by -12.6% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Bio-Techne?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Bio-Techne?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Bio-Techne have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Bio-Techne pay?
Over the past 12 months, Bio-Techne paid a dividend of 0.4 USD . This corresponds to a dividend yield of about 0.61 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.39 USD.
What is the dividend yield of Bio-Techne?
The current dividend yield of Bio-Techne is 0.61 %.
When does Bio-Techne pay dividends?
Bio-Techne pays a quarterly dividend. This is distributed in the months of June, September, December, March.
How secure is the dividend of Bio-Techne?
Bio-Techne paid dividends every year for the past 22 years.
What is the dividend of Bio-Techne?
For the upcoming 12 months, dividends amounting to 0.39 USD are expected. This corresponds to a dividend yield of 0.6 %.
In which sector is Bio-Techne located?
Bio-Techne is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bio-Techne from 2/28/2025 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 2/14/2025.
When did Bio-Techne pay the last dividend?
The last dividend was paid out on 2/28/2025.
What was the dividend of Bio-Techne in the year 2024?
In the year 2024, Bio-Techne distributed 0.4 USD as dividends.
In which currency does Bio-Techne pay out the dividend?
The dividends of Bio-Techne are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Bio-Techne
Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
